New pill takes aim at Hard-to-Treat myeloma

NCT ID NCT05651932

Recruiting now Disease control Sponsor: K36 Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called KTX-1001 in people with multiple myeloma that has returned or not responded to prior treatments. The drug works by blocking a protein that helps myeloma cells grow. The study will enroll 165 adults and will also test KTX-1001 combined with other myeloma drugs. The main goals are to find a safe dose and see if the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KTX-1001 (an oral drug that targets a protein linked to myeloma growth), sometimes combined with dexamethasone, mezigdomide, or carfilzomib
What this could lead to: If successful, this could provide a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 165 participants, so the drug may prove unsafe or ineffective. It is not a cure and patients will need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MYELOMA MYELOMA MULTIPLE

Contacts and locations

Show contact details

Locations

Atrium Health, Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu
RECRUITING

Nantes, France
Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers)
RECRUITING

Poitiers, France
Clínica Universidad de Navarra
RECRUITING

Pamplona, Navarre, 31008, Spain
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke University Hospital
RECRUITING

Durham, North Carolina, 27705, United States
Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Hospital ClÃ-nic de Barcelona
RECRUITING

Barcelona, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, Spain
Institut Universitaire du Cancer de Toulouse - Oncopole
RECRUITING

Toulouse, France
Instituto de Investigacion Biomedica de Salamanca (IBSAL)
RECRUITING

Salamanca, Spain

Contact Email: •••••@•••••
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic - Transplant Center - Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
Mayo Clinic Hospital - Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Memorial Sloan-Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
The Winship Cancer Institute of Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic
RECRUITING

San Francisco, California, 94143, United States
Universitaire de Lille
RECRUITING

Villeneuve-d'Ascq, France, France
University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital)
RECRUITING

Toronto, Ontario, M5G 2C4, Canada
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.